首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗臨床開發

市場調查報告書

商品編碼

1983179

周邊神經病變治療市場：依適應症、治療方法、最終使用者和地區分類。

Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography

出版日期: 2026年02月26日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，周邊神經病變治療市場規模將達到 20.917 億美元，到 2033 年將達到 27.159 億美元。預計從 2026 年到 2033 年，該市場將以 3.8% 的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	2,091,700,000 美元
效能數據	2020-2024	預測期	2026-2033
預測期（2025-2032 年）複合年成長率	3.80%	預計金額（2033 年）	27.159億美元

周邊神經病變是周邊神經的一種疾病。這些神經負責在中樞神經系統（大腦和脊髓）與身體其他部位之間傳遞訊息。周邊神經病變可由創傷、感染疾病、代謝紊亂、遺傳因素和接觸毒素引起。其中最常見的原因之一是糖尿病。由第1型或第2型糖尿病引起的周邊神經病變稱為糖尿病性神經病變。周邊神經病變患者通常將疼痛描述為刺痛、灼痛或麻刺感。在許多情況下，症狀會改善，尤其是在病因是可治療的疾病時。Lyrica）和度洛西汀（Cymbalta）等藥物可以緩解周邊神經病變的疼痛。

市場動態

全球周邊神經神經病變治療市場的主要企業正專注於市場滲透策略，例如產品上市和核准批准，預計這些策略將在預測期內推動市場成長。例如，2019年7月，印度製藥公司Alembic Pharmaceuticals Limited宣布，其用於治療周邊神經病變疼痛的Pregabalin膠囊已獲得美國食品藥物管理局（FDA）的簡化新藥申請（ANDA）核准。此外，多個政府機構正致力於資助學術研究機構，以進行化療引起的周邊神經神經病變治療的研究和開發，預計這也將在預測期內推動市場成長。例如，2018年11月，美國國家癌症研究所（NCI）向美國研究機構印第安納大學醫學院撥款230萬美元。這項投資旨在加速一種名為APX3330的小分子標靶的研發，以預防或改善抗癌藥物引起的化療引起的周邊神經病變（CIPN）。

本報告的主要特點

本報告對全球周邊神經神經病變治療市場進行了詳細分析，包括預測期（2025-2032 年）的市場規模和複合年成長率，以 2024 年為基準年。
此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本節根據以下參數介紹全球周邊神經病變治療市場主要企業的概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球周邊神經病變治療市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球周邊神經病變治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
- Abbott Laboratories
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Johnson &Johnson
- Reddy's Laboratories Ltd
- Pfizer, Inc.
- Cipla Inc.
- Lupin Limited
- Averitas Pharma, Inc.
- NeuroBo Pharmaceuticals, Inc

第9章

分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI4363

Peripheral Neuropathy Treatment Market is estimated to be valued at USD 2,091.7 Mn in 2026 and is expected to reach USD 2,715.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,091.7 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	3.80%	2033 Value Projection:	USD 2,715.9 Mn

Peripheral neuropathy is a disorder of the peripheral nerves. These nerves send messages between the central nervous system, the brain and the spinal cord, and the rest of the body. Peripheral neuropathy can result from traumatic injuries, infections, metabolic problems, inherited causes, and exposure to toxins. One of the most common causes is diabetes. Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. Individual with peripheral neuropathy generally describe the pain as stabbing, burning or tingling. In many cases, symptoms improve, especially if caused by a treatable condition. Medications such as Lyrica, Cymbalta, etc can reduce the pain of peripheral neuropathy.

Market Dynamics

Key players operating in the global peripheral neuropathy treatment market are focusing on adoption growth strategies such as product launch, and approval which are expected to drive the market growth during the forecast period. For instance, in July 2019, Alembic Pharmaceuticals Limited, an Indian pharmaceutical company, announced that it received the approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pregabalin Capsules that is used for peripheral neuropathic pain. Moreover, various government agencies focusing on investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy which is expected to drive the market growth over forecast period. For instance, in November 2018, the U.S. National Cancer Institute awarded/invested US$ 2.3 Mn in Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs.

Key features of the study

This report provides an in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global peripheral neuropathy treatment market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy's Laboratories Ltd, Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., and NeuroBo Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.

Market Segmentation

By Indication
- Diabetic Peripheral Neuropathy
- Chemotherapy-induced Peripheral Neuropathy
- Idiopathic Peripheral Neuropathy
- Others
By Treatment
- Pharmacological Therapies
- Pain Relievers
- Anti-seizure Medications
- Anti-depressants
- Non-pharmacological Therapies
- Transcutaneous Electrical Nerve Stimulation
- Plasma Exchange
- Others
By End User
- Hospital
- Ambulatory Centers
- Others
By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- Abbott Laboratories
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Johnson & Johnson
- Reddy's Laboratories Ltd
- Pfizer, Inc.
- Cipla Inc.
- Lupin Limited
- Averitas Pharma, Inc.
- NeuroBo Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Indication
- Market Snapshot, By Treatment
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Pipeline Analysis
Reimbursement Scenario
Epidemiology
PEST Analysis
Regulatory Scenario
New Product Approvals/Launches
Acquisition and Collaboration
Market Trends

4. Global Peripheral Neuropathy Treatment Market, By Indication, 2026-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Diabetic Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Mn)
Chemotherapy-induced Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Mn)
Idiopathic Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Mn)

5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2026-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
  - Pain Relievers
  - Anti-seizure Medications
  - Anti-depressants
Non-pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
  - Transcutaneous Electrical Nerve Stimulation
  - Plasma Exchange
  - Others

6. Global Peripheral Neuropathy Treatment Market, By End User, 2026-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
Ambulatory Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

7. Global Peripheral Neuropathy Treatment Market, By Region, 2026-2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2028
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
- Abbott Laboratories
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Eli Lilly and Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Johnson & Johnson
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Reddy's Laboratories Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Pfizer, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Cipla Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Lupin Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Averitas Pharma, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- NeuroBo Pharmaceuticals, Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

9. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

周邊神經病變治療市場：依適應症、治療方法、最終使用者和地區分類。

Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography

市場動態

目錄

第1章：分析目標與假設

第2章市場展望

第3章：市場動態、監管與趨勢分析

第4章：全球周邊神經神經病變治療市場：依適應症分類（2026-2033 年）

第5章：全球周邊神經病變治療市場：依治療方法分類（2026-2033 年）

第6章：全球周邊神經病變治療市場：依最終使用者分類（2026-2033 年）

第7章全球周邊神經神經病變治療市場：依地區分類（2026-2033 年）

第8章競爭情勢

第9章

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Peripheral Neuropathy Treatment Market, By Indication, 2026-2033, (US$ Mn)

5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2026-2033, (US$ Mn)

6. Global Peripheral Neuropathy Treatment Market, By End User, 2026-2033, (US$ Mn)

7. Global Peripheral Neuropathy Treatment Market, By Region, 2026-2033, (US$ Mn)

8. Competitive Landscape

9. Section

周邊神經病變治療市場：依適應症、治療方法、最終使用者和地區分類。

Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography

市場動態

目錄

第1章：分析目標與假設

第2章 市場展望

第3章：市場動態、監管與趨勢分析

第4章：全球周邊神經神經病變治療市場：依適應症分類（2026-2033 年）

第5章：全球周邊神經病變治療市場：依治療方法分類（2026-2033 年）

第6章：全球周邊神經病變治療市場：依最終使用者分類（2026-2033 年）

第7章 全球周邊神經神經病變治療市場：依地區分類（2026-2033 年）

第8章 競爭情勢

第9章

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Peripheral Neuropathy Treatment Market, By Indication, 2026-2033, (US$ Mn)

5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2026-2033, (US$ Mn)

6. Global Peripheral Neuropathy Treatment Market, By End User, 2026-2033, (US$ Mn)

7. Global Peripheral Neuropathy Treatment Market, By Region, 2026-2033, (US$ Mn)

8. Competitive Landscape

9. Section

第2章市場展望

第7章全球周邊神經神經病變治療市場：依地區分類（2026-2033 年）

第8章競爭情勢